-
Results from a Phase 1 single-escalating dose study of Minerva Neurosciences' (NASDAQ:NERV +1%) schizophrenia candidate MIN-101 (roluperidone) showed a favorable safety profile and possibly an expanded therapeutic window.
- It says the data suggest that roluperidone may be effective in treating schizophrenia patients with psychosis at higher doses than those being used in the Phase 3 study.
- Topline data from the Phase 3 trial should be available in mid-2019. A previously announced Phase 2b study was successful.
- The company will host a key opinion leader (KOL) event tomorrow, November 20, in New York to discuss roluperidone and its potential use in treating negative symptoms of schizophrenia.